MONTREAL, CANADA--(Marketwire - April 14, 2008) - Theratechnologies (TSX: TH) announced today that the last patient has completed 26 weeks of treatment in the confirmatory Phase 3 trial testing tesamorelin in HIV-associated lipodystrophy. The Company now expects to be in a position to present top-line, 26-week results of this confirmatory Phase 3 trial by the end of the first half of 2008.
